Search results for: Determining Value
Filter search results
Around the world in HTAs: China – From fragmentation to function
2 September 2025
…aimed to control spending, it often discouraged innovation and failed to reflect the value of new drugs. Hospitals, which were allowed to mark up drug prices, relied heavily on pharmaceutical…
Making Outcome-based Payments a Reality in the NHS: A Research Collaboration between OHE, RAND Europe and King’s College London
15 May 2018
…of identifying measurable outcomes that can reflect the value of new drugs through the use of real-world evidence. The joint research team has a wealth of experience in the…
HTA and Payment Mechanisms for New Drugs to Tackle AMR
1 September 2019
…from investment in antibiotics. Value assessment methods recognising the value of new antibiotics to the whole health system are needed to help match the size of the required monetary incentives…
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
1 December 2006
Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs). Methods We modelled the R&D process…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…of appropriability, a concept that reflects innovators’ capacity to capture or appropriate the added value created by successful innovation. Problems can arise if the amount of appropriation is too…
OHE at ISPOR Europe 2018
…Value Based Pricing Versus WHO Fair Pricing. Which Delivers Universal Health Coverage? The World Health Organisation (WHO) is arguing that value-based pricing alone is not a viable basis for the…
The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe
2 June 2023
…economic benefits, genomic testing is associated with broader elements of value, especially the ‘value of knowing’. Whilst the prevailing barriers and opportunities differ across countries, we have specified three generalisable…
The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?
25 June 2020
…of Health Economics. Available: https://www.cgdev.org/publication/blueprintmarket-driven-value-based-advance-commitment-tuberculosis Chalkidou K, Towse A, Silverman R, et al. (2020). Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end…